Journal of Clinical Medicine, Volume 14, Issue 8
2025 April-2 - 323 articles
Cover Story: Metastatic hormone-sensitive prostate cancer (mHSPCa) may present de novo or as significant disease progression and typically requires systemic treatment. Recently, triplet therapy—integrating ADT, docetaxel, and an ARSI—has emerged as an effective approach, particularly in high-volume metastatic disease, as supported by ARASENS and PEACE-1. Advances in imaging, such as PSMA PET-CT, have improved disease detection, allowing for earlier detection of metastasis and timely initiation of appropriate therapy. Genomic profiling has enabled the development of biomarker-driven, personalized treatment strategies. As novel therapies, targeted agents, and immunotherapies undergo investigation, optimizing treatment selection based on disease burden, molecular characteristics, and patient factors will be essential. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.